RxDoctor Payments Data

Jeffery Long, MD

Family Medicine · Herscher, ILNPI 1932284700

Payments from drug & device makers

$9,658in general payments, 2019–2025

Across 606 payments — averaging $15.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • Boehringer Ingelheim$993
  • AstraZeneca$842
  • Pfizer$649
  • Novartis$492
  • Amgen$359
  • plus $5K from 41 others

What the payments were for

  • Food & beverage$9,611100%
  • Education$470%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$9,658 in reported general payments places this provider in the 95th percentile of 4,116 family medicine providers in Illinois.

See all family medicine providers in Illinois

Medicare billing

Part B allowed, 2024
$277,199
Medicare patients
538
Services billed
3,240

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin161$219,561
OzempicSemaglutide110$149,032
FarxigaDapagliflozin Propanediol93$122,765
Tresiba Flextouch U-200Insulin Degludec57$95,997
TrulicityDulaglutide25$55,179
MounjaroTirzepatide43$48,202
EliquisApixaban38$46,725
XareltoRivaroxaban47$43,413
ArexvyRsvpref3 Antigen/As01e/Pf129$40,196
GemtesaVibegron23$32,806
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr46$24,907
MyrbetriqMirabegron26$24,745
TradjentaLinagliptin20$22,955
Breztri AerosphereBudesonide/Glycopyr/Formoterol21$22,633
RybelsusSemaglutide13$20,247

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$993$242,516181 claims
Novo NordiskOzempic, Rybelsus$1,549$169,278123 claims
AstraZenecaFarxiga, Breztri Aerosphere$842$145,398114 claims
Lilly USA, LLCTrulicity, Mounjaro$306$103,38168 claims
GSKArexvy, Anoro Ellipta, Breo Ellipta, Shingrix$289$86,449238 claims
PfizerEliquis$649$46,72538 claims
Johnson & JohnsonXarelto$167$43,41347 claims
Sumitomo Pharma America, Inc.Gemtesa$99$32,80623 claims
Astellas Pharma US IncMyrbetriq$123$24,74526 claims
MerckJanumet, Januvia$293$24,34328 claims
NovartisEntresto$492$9,69711 claims
AbbVieSynthroid$340$8,94282 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,116 family medicine providers in Illinois.

Other family medicine in Herscher

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →